Registration number: 16186675

Aexis Medical Limited

Contents

Company Information	1
Statement of Financial Position	2
Notes to the Financial Statements	3 to 7

Aexis Medical Limited

Company Information

Directors

A W Myers D Vanbiervliet

Registered office

130 Shaftesbury Avenue 2nd Floor London W1D 5EU

Auditor

Brebners Chartered Accountants & Statutory Auditor 130 Shaftesbury Avenue London W1D 5AR

Aexis Medical Limited

Statement of Financial Position as at 31 December 2025

	Note	2025 £
Fixed assets
Tangible assets	5	285
Current assets
Debtors	6	87,260
Cash at bank and in hand		50,445
		137,705
Creditors: Amounts falling due within one year	7	(34,113)
Net current assets		103,592
Total assets less current liabilities		103,877
Creditors: Amounts falling due after more than one year	7	(308,968)
Net liabilities		(205,091)
Capital and reserves
Called up share capital		1
Retained earnings		(205,092)
Shareholders' deficit		(205,091)

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Statement of Income and Retained Earnings has been taken.

Approved and authorised by the Board on 5 August 2026 and signed on its behalf by:
 

.........................................

D Vanbiervliet

Director

Company registration number: 16186675

Aexis Medical Limited

Notes to the Financial Statements for the Period from 15 January 2025 to 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
130 Shaftesbury Avenue
2nd Floor
London
W1D 5EU

The principal activity of the company is that of the sale of medical software for hospitals and clinics in the UK.

2	Audit Report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 6 August 2026 was Martin Widdowson, who signed for and on behalf of Brebners.

3	Accounting policies

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' Section 1A and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except any items disclosed in the accounting policies as being shown at fair value and are presented in sterling, which is the functional currency of the entity.

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Going concern

The company made a loss for the year ended 31 December 2025 and had net liabilities of £205,091 at that date but with net current assets of £103,592.

The company is reliant upon working capital provided by its parent company amounting £308,968 at 31 December 2025 which is not repayable until 31 December 2030. The parent company has undertaken to provide further working capital if required.

On the basis of the above, the director believes that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the director continues to adopt the going concern basis in preparing the financial statements.

Aexis Medical Limited

Notes to the Financial Statements for the Period from 15 January 2025 to 31 December 2025

Revenue recognition

Turnover represents the fair value of the consideration received or receivable for services provided in the ordinary course of the company's activities; excluding VAT or other sales taxes.

Software licenses and associated maintenance contracts: The company may provide customers with: a software license granting a right to use the software, and ongoing maintenance and support services. These are assessed to determine whether they represent separate performance obligations based on whether they are distinct within the context of the contract.

Software licenses: If the license provides the customer with a right to use the software as it exists at the point in time when the license is granted (with no ongoing updates required for functionality), revenue is recognized at the point in time when the customer obtains control of the license and can benefit from it. If the license includes continuous updates, upgrades, or enhancements that are essential to the software’s functionality, the license and maintenance are combined as a single performance obligation, and revenue is recognized over the contract term.

Maintenance and support services: Revenue from maintenance, including technical support, updates, or upgrades not essential to functionality, is recognized over time, typically on a straight-line basis over the service period, as the customer simultaneously receives and consumes the benefits. The transaction price is allocated to performance obligations based on relative stand-alone selling prices.

Professional services: Revenue from consulting services is recognised over time, as the services are delivered. Fees are charged based on the actual hours worked at agreed hourly rates. This reflects the transfer of control to the customer as services are performed. The stage of completion is measured based on hours incurred relative to the total expected hours to complete the service.

Hardware and consumables related revenue: Revenue from sale of label, printers and “Take-a-number” machines is recognised at the point in time when control of the asset is transferred to the customer, generally on delivery of the asset at the customer’s location.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Aexis Medical Limited

Notes to the Financial Statements for the Period from 15 January 2025 to 31 December 2025

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Office Equipment	25% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

4	Staff numbers

The average number of persons employed by the company during the period, was 2.

Aexis Medical Limited

Notes to the Financial Statements for the Period from 15 January 2025 to 31 December 2025

5	Tangible assets

	Office Equipment  £	Total £
Cost or valuation
Additions	299	299
At 31 December 2025	299	299
Depreciation
Charge for the period	14	14
At 31 December 2025	14	14
Carrying amount
At 31 December 2025	285	285

6

Debtors

	2025 £
Other debtors	87,260
	87,260

7

Creditors

Creditors: amounts falling due within one year

	2025 £
Trade creditors	5,199
Taxation and social security	9,202
Accruals and deferred income	18,705
Other creditors	1,007
	34,113